The Latest Breaking News from CYTK

Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise

Cytokinetics (NASDAQ:CYTK) executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug’s label, REMS program and recent clinical data in hypertrophic cardiomyopathy during a discussion hosted by RBC Capi

MarketBeat · May 22

Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action?

Shares of Cytokinetics, Inc. (NASDAQ:CYTK) are trading sharply higher Tuesday after the biopharmaceutical company presented new data highlighting the long-term safety and efficacy of its investigational drug, aficamten, at the European Society of Cardiology Congress 2025. Here’s what investors need to know.

Benzinga · Sep 2, 2025

Cytokinetics: Q1 Earnings Insights

Cytokinetics (NASDAQ:CYTK) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics missed estimated earnings by 8.51%, reporting an EPS of $-1.02 versus an estimate of $-0.94.

Benzinga · May 4, 2022